- Condition: Atrial Fibrillation Ablation
Intervention: Drug: Adenosine arm
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Not yet recruiting - verified May 2012 - Conditions: Sickle Cell Disease; Sickle Cell Anemia
Interventions: Drug: regadenoson infusion with contrast-enhanced ultrasound; Procedure: contrast-enhanced ultrasound; Procedure: contrast-enhanced ultrasound; Procedure: contrast-enhanced ultrasound
Sponsors: Blood Center of Wisconsin; Blood Center of Wisconsin; Medical College of Wisconsin; LaJolla Institute for Allergy and Immunology; University of Illinois; Oregon Health and Science University
Not yet recruiting - verified March 2012 - Condition: Supraventricular Tachycardia
Interventions: Drug: Dexmedetomidine; Drug: Adenosine
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified February 2012 - Conditions: Coronary Artery Disease; Myocardial Perfusion Abnormalities
Intervention: Drug: Regadenoson; Optison
Sponsors: University of Nebraska; Thomas R. Porter, MD; Astellas Pharma US, Inc.; GE Healthcare
Not yet recruiting - verified December 2011 - Condition: Coronary Artery Disease
Intervention: Drug: FFR Measurement with IV Adenoscan® then with Regadenoson
Sponsors: Ochsner Health System; Ochsner Health System; Astellas Pharma Global Development, Inc.
Recruiting - verified March 2012 - Condition: Chronic Hepatic Impairment
Intervention: Drug: Preladenant
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Intervention: Drug: Regadenoson
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Astellas Pharma Global Development, Inc.
Recruiting - verified September 2011 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Biological: modified T cells
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Mesothelioma
Interventions: Drug: Pentostatin; Drug: Cyclophosphamide; Drug: SS1P
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Chronic Lymphocytic Leukemia; B-Cell Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine; Drug: Pentostatin; Drug: Ofatumumab
Sponsors: Thomas Jefferson University; Thomas Jefferson University; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Coronary Artery Disease (CAD)
Interventions: Drug: regadenoson; Radiation: technetium; Radiation: Contrast
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson (Lexiscan ®).
Interventions: Drug: Aminophylline; Drug: Placebo
Sponsors: Rush University Medical Center; Rush University Medical Center; John H. Stroger Hospital
Recruiting - verified October 2011 - Condition: Coronary Artery Disease
Interventions: Drug: adenosine; Drug: regadenoson; Drug: Adenosine
Sponsors: St. Louis University; St. Louis University; University of Florida; Astellas Pharma US, Inc.
Recruiting - verified July 2011 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Drug: INO-8875; Drug: Placebo
Sponsors: Inotek Pharmaceuticals Corporation; Inotek Pharmaceuticals Corporation
Recruiting - verified August 2011 - Condition: Coronary Artery Disease
Interventions: Drug: Exercise plus Regadenoson (Lexercise); Drug: Regadenoson (Lexiscan)
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified June 2011 - Condition: Sickle Cell Disease
Intervention: Drug: Lexiscan
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Children's Hospital Boston; Washington University School of Medicine; LaJolla Institute for Allergy and Immunology; National Heart, Lung, and Blood Institute (NHLBI); Astellas Pharma Global Development, Inc.
Recruiting - verified June 2011 - Condition: Acute Coronary Syndrome
Intervention: Drug: ADP receptor inhibitors
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin; Drug: Rituximab; Drug: Bendamustine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Hematopoietic/Lymphoid Cancer; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Drug: cyclophosphamide; Biological: ofatumumab; Procedure: laboratory biomarker analysis; Other: flow cytometry; Genetic: protein expression analysis
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Conditions: Coronary Artery Disease; Diabetes Mellitus Type 2
Intervention: Drug: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Sponsors: Mayo Clinic; Mayo Clinic; University of Nebraska; Astellas Pharma US, Inc.; Lantheus Medical Imaging
Recruiting - verified January 2012 - Conditions: Parkinson Disease; Huntington Disease
Intervention: Drug: [123I]MNI-420
Sponsors: Institute for Neurodegenerative Disorders; Institute for Neurodegenerative Disorders
Recruiting - verified February 2012 - Condition: Sinusitis
Intervention:
Sponsors: University of Washington; Greg Davis
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Graft-Versus-Host Disease; Engraftment Syndrome
Interventions: Drug: Pentostatin; Drug: Sirolimus; Drug: Cyclophosphamide; Procedure: Allogeneic Hematopoietic Stem Cell Transplant; Procedure: Th2 Cell Transplantation; Drug: Th2 Cells in Allogeneic HSCT
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Coronary Artery Disease
Intervention:
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified May 2010 - Conditions: Leukemia; Lymphoma
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: pentostatin
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Severe Combined Immunodeficiency
Intervention: Biological: ADA gene transfer
Sponsors: University of California, Los Angeles; University of California, Los Angeles; FDA Office of Orphan Products Development; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Conditions: Ischemia; Coronary Disease
Intervention:
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; Department of Defense
Recruiting - verified July 2011 - Conditions: Leukemia; Chronic Lymphocytic Leukemia
Intervention: Drug: 8-Chloro-Adenosine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); FDA Office of Orphan Products Development
Recruiting - verified March 2012 - Conditions: Coronary Artery Disease; Angina Pectoris; Unstable Angina; Acute Coronary Syndrome
Interventions: Procedure: Coronary Computed Tomography Angiography; Procedure: Stress Nuclear Myocardial Perfusion Imaging
Sponsors: Montefiore Medical Center; Montefiore Medical Center; American Heart Association; Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified June 2011 - Condition: Heart Disease
Intervention: Procedure: noninvasive tests
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012 - Condition: Lung Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Drug: CD34+ cells transduced with ADA retrovir
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012
 |
Adenosine Clinical Trials |
